FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileHemab Therapeutics Holdings, Inc. Common Stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
COAG
Hemab Therapeutics Holdings, Inc. Common Stock Stock AnalysisComprehensive stock analysis for Hemab Therapeutics Holdings, Inc. Common Stock (COAG) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCOAG
COAG
Hemab Therapeutics Holdings, Inc. Common Stock
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
COAG
  1. Home
  2. Stocks
  3. Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

🇺🇸COAG•NASDAQ

Hemab Therapeutics Holdings, Inc. Common Stock

🇺🇸COAG•NASDAQ
Market cap
$1.84B

Your view on COAG

Mkt Cap
$1.84B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Hemab Therapeutics Holdings, Inc. Common Stock

Industry
Biotechnology
Sector
Healthcare
CEO
Benny Sorensen
Headquarters
101 Main Street, Cambridge, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Benny Sorensen
Headquarters
101 Main Street, Cambridge, MA, US
Description

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies.

The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency.

Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs.

Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Hemab Therapeutics Holdings, Inc. Common Stock. Starting points for Hemab Therapeutics Holdings, Inc. Common Stock: EPS -$2.00, beta 1.85 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Hemab Therapeutics Holdings, Inc. Common Stock. Trailing twelve-month EPS for Hemab Therapeutics Holdings, Inc. Common Stock stands at -$2.00. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
Analysts' target$54.50average of 6 firms, last 12 months
Current price—

Buy

Targets, low to high

$54.50

Low $36.00

Middle $55.00

High $70.00

Analyst ratings

3 firms, last 12 months
  • Strong Buy0
  • Buy3
  • Hold0
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.57−$0.61−$2.97−$2.52
Lowest estimate−$0.58−$0.62−$2.98−$2.61
Highest estimate−$0.56−$0.59−$2.96−$2.41
Number of analysts3244
A year ago—−$23.98−$2.331—
Growth vs a year ago—+97.5%——

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$0.00$0.00$0.00$0.00
Lowest estimate$0.00$0.00$0.00$0.00
Highest estimate$0.00$0.00$0.00$0.00
Number of analysts0000
A year ago—$0.00$0.00—
Growth vs a year ago————
Recent rating and target changes (12)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Hemab Therapeutics Holdings, Inc. Common Stock. Hemab Therapeutics Holdings, Inc. Common Stock has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold COAG16 companies · 8 funds
Compare COAG with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
DMRADamora Therapeutics, Inc.HealthcareBiotechnology$1.4B
IRONDisc Medicine, Inc.HealthcareBiotechnology$2.9B
QUREuniQure N.V.HealthcareBiotechnology$1.4B
RLYBRallybio CorporationHealthcareBiotechnology$83.3M
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
AUPHAurinia Pharmaceuticals Inc.HealthcareNASDAQ$2.0B
AURAAura Biosciences, Inc.HealthcareNASDAQ$715.0M
AURXNuo Therapeutics, Inc.HealthcareOTC$72.4M
AUTLAutolus Therapeutics plcHealthcareNASDAQ$241.7M
AVBPArriVent BioPharma, Inc. Common StockHealthcareNASDAQ$544.1M
AVCTFAvacta Group PlcHealthcareOTC$372.9M
AVE.AXAvecho Biotechnology LimitedHealthcareASX—
AVEFFAvecho Biotechnology LimitedHealthcareOTC$13.4M
AVIRAtea Pharmaceuticals, Inc.HealthcareNASDAQ$318.0M
AVLNAvalyn Pharma Inc. Common StockHealthcareNASDAQ$1.3B
AVTXAvalo Therapeutics, Inc.HealthcareNASDAQ$390.9M
AVXLAnavex Life Sciences Corp.HealthcareNASDAQ$54.8M
ETFs holding Hemab Therapeutics Holdings, Inc. Common Stock
TickerFundFund assets% of the fund
XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.22%
IWMiShares Russell 2000 ETF$76.6B in assets0.03%
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
VXFVanguard Extended Market ETF$30.2B in assets0.01%
TMSLT. Rowe Price Small-Mid Cap ETF$3.2B in assets0.05%
VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.03%
FBCGFidelity Blue Chip Growth ETF$7.3B in assets0.03%
RSSLGlobal X - Russell 2000 ETF$1.4B in assets0.03%

Largest holders first, then the funds most concentrated in COAG.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Hemab Therapeutics Holdings, Inc. Common Stock, and how their positions are changing. At a $1.84B market value, institutional positions materially move Hemab Therapeutics Holdings, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Hemab Therapeutics Holdings, Inc. Common Stock executives and directors. Shares of Hemab Therapeutics Holdings, Inc. Common Stock have traded between $23.00 and $53.33 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Hemab Therapeutics Holdings, Inc. Common Stock. Coverage tracks Hemab Therapeutics Holdings, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Hemab Therapeutics Holdings, Inc. Common Stock.

COAG AnalysisFair
Past
3
Growth
2
Health
5
Profit
1
Value
1